x
Filter:
Filters applied
- Tumor Board Papers
Publication Date
Please choose a date range between 2018 and 2021.
Author
- Konstantinopoulos, Panagiotis A2
- Abu-Rustum, Nadeem R1
- Addley, Helen C1
- Aghajanian, Carol1
- Aubrey, Christa1
- Awtrey, Christopher S1
- Boitano, Teresa1
- Campos, Susana1
- Cavaliere, AF1
- Cefalo, MG1
- Crotzer, David1
- Dandoy, Christopher E1
- Dasgupta, Roshni1
- Dilley, Sarah E1
- Fagotti, A1
- Frazer, Jenny L1
- Gatius, Sonia1
- Gil, Mabel1
- Glaze, Sarah1
- Gockley, Allison A1
- Goebel, Emily A1
- Hook, C Elizabeth1
- Horowitz, Neil S1
- Jackson, Claire R1
- Kobel1
Keyword
- Ovarian2
- Abscopal effect1
- AYA1
- Cervical cancer1
- Chemotherapy1
- Cowden syndrome1
- Germ cell tumor1
- Germline1
- Growing teratoma syndrome1
- Gynecologic oncology1
- Immature teratoma1
- Immunotherapy1
- Low dose radiation1
- Neoadjuvant chemotherapy1
- Obstetric outcome1
- Pathology1
- Pediatric oncology1
- Pregnancy1
- PTEN mutation1
- Radical hysterectomy1
- Rhabdoid1
- SCCOHT1
- SMARCA41
- Surgery1
- Targeted therapy1
Tumor Board Papers
9 Results
- Gynecologic Oncology Tumor Board Presentation
Diagnosis and management of an endometrial cancer patient with Cowden syndrome
Gynecologic OncologyVol. 163Issue 1p14–21Published online: August 23, 2021- Beryl L. Manning-Geist
- Sonia Gatius
- Ying Liu
- Mabel Gil
- Arnaud Da Cruz Paula
- Noemi Tuset
- and others
Cited in Scopus: 1Somatic PTEN alterations are common in endometrial carcinoma (EC), but in rare cases PTEN mutations are associated with inherited syndromes. Here, we present a case of Cowden syndrome-associated EC. We discuss clinical, pathologic and molecular features of her tumor and PTEN-mutated EC, inherited syndromes predisposing to EC and PTEN-targeted therapies. - Gynecologic Oncology Tumor Board Presentation
Immunotherapy combined with high- and low-dose radiation to all sites leads to complete clearance of disease in a patient with metastatic vaginal melanoma
Gynecologic OncologyVol. 161Issue 3p645–652Published online: March 29, 2021- Duygu Sezen
- Roshal R. Patel
- Christine Tang
- Michaela Onstad
- Priyadharsini Nagarajan
- Sapna P. Patel
- and others
Cited in Scopus: 7A 73-year-old woman with metastatic vaginal mucosal melanoma that had progressed on ipilimumab and nivolumab experienced clinical and radiographic complete response to dual checkpoint inhibitor immunotherapy given in combination with high-dose plus low-dose radiation. General characteristics and treatment options in this disease are highlighted. - Gynecologic Oncology Tumor Board Presentation
Implications for management of ovarian cancer in a transgender man: Impact of androgens and androgen receptor status
Gynecologic OncologyVol. 161Issue 2p342–346Published online: March 1, 2021- Christa Aubrey
- Nathalie Saad
- Martin Köbel
- Fiona Mattatall
- Gregg Nelson
- Sarah Glaze
Cited in Scopus: 2A 36-year-old transgender man (assigned female at birth) on exogenous testosterone therapy was found to have stage IIA ovarian endometrioid carcinoma, and underwent adjuvant chemotherapy. Diffuse androgen receptor expression in the tumor initiated a multidisciplinary discussion regarding the safety of continuing exogenous testosterone as gender-affirming hormone therapy. - Gynecologic Oncology Tumor Board Presentation
Small cell carcinoma of the ovary hypercalcemic type (SCCOHT): Comprehensive management of a newly diagnosed young adult
Gynecologic OncologyVol. 158Issue 3p538–546Published online: July 10, 2020- Joseph G. Pressey
- Christopher E. Dandoy
- Luke E. Pater
- Julie Sroga Rios
- Rebecca Sisson
- Roshni Dasgupta
- and others
Cited in Scopus: 3SCCOHT is an aggressive malignancy linked to alterations of SMARCA4. We describe the diagnosis and therapy of a 32 year old who received multi-agent chemotherapy and underwent a second look operation with HIPEC followed by high-dose chemotherapy with stem cell transplant. Supportive care, oncofertility, and genetic counseling are described. - Gynecologic Oncology Tumor Board Presentation
Recurrent ovarian immature teratoma in a 12-year-old girl: Implications for management
Gynecologic OncologyVol. 154Issue 2p259–265Published online: June 5, 2019- Jenny L. Frazer
- C. Elizabeth Hook
- Helen C. Addley
- Claire R. Jackson
- John A. Latimer
- James C. Nicholson
- and others
Cited in Scopus: 9Immature teratomas (IT) are rare and recurrences uncommon. A 12-year-old female with grade 3 (high-grade) ovarian IT underwent surgical resection but experienced early recurrences; the first was treated with surgery but the second was metastatic and managed with chemotherapy, resulting in growing-teratoma-syndrome and need for further surgery. She now remains well in uneventful clinical follow-up. We believe chemotherapy could be reserved for very carefully selected recurrent IT cases, which may alter the natural history of disease. - Gynecologic Oncology Tumor Board Presentation
Diagnosis and management of a recurrent polymerase-epsilon (POLE)-mutated endometrial cancer
Gynecologic OncologyVol. 153Issue 3p471–478Published online: March 29, 2019- Jennifer Taylor Veneris
- Elizabeth K. Lee
- Emily A. Goebel
- Marisa R. Nucci
- Neal Lindeman
- Neil S. Horowitz
- and others
Cited in Scopus: 15Polymerase-epsilon (POLE)-mutated carcinomas are a rare, but well-known subtype of endometrial cancer. While typically associated with good prognosis, recurrences are documented. Here we present a case of recurrent POLE-mutated endometrial cancer, discuss pathologic features, current methods of molecular classification, and explore therapeutic implications for the POLE-mutation phenotype. - Gynecologic Oncology Tumor Board Presentation
Locally advanced cervical cancer complicating pregnancy: A case of competing risks from the Catholic University of the Sacred Heart in Rome
Gynecologic OncologyVol. 150Issue 3p398–405Published online: July 4, 2018- R. De Vincenzo
- L. Tortorella
- C. Ricci
- A.F. Cavaliere
- G.F. Zannoni
- M.G. Cefalo
- and others
Cited in Scopus: 13A case of stage IB2 cervical cancer at 27 weeks of pregnancy, treated with neoadjuvant chemotherapy followed by radical Cesarean hysterectomy with full pelvic and infra-mesenteric lymphadenectomy, and adjuvant chemo-radiation is described. While she remains without disease, her baby was diagnosed with acute myelogenous leukemia. We highlight the pre-operative work-up, treatment options, safety, feasibility, and outcomes for the mother and her fetus. - Gynecologic Oncology Tumor Board Presentation
Durable response in a woman with recurrent low-grade endometrioid endometrial cancer and a germline BRCA2 mutation treated with a PARP inhibitor
Gynecologic OncologyVol. 150Issue 2p219–226Published online: June 21, 2018- Allison A. Gockley
- David L. Kolin
- Christopher S. Awtrey
- Neal I. Lindeman
- Ursula A. Matulonis
- Panagiotis A. Konstantinopoulos
Cited in Scopus: 20A 42-year-old woman with a germline BRCA2 mutation and recurrent low-grade endometrioid endometrial adenocarcinoma experienced clinical and radiographic response to the poly (ADP ribose) polymerase (PARP) inhibitor, olaparib. Molecular and treatment factors are discussed. - Gynecologic Oncology Tumor Board Presentation
Treatment of low-grade endometrial stromal sarcoma in a nulligravid woman
Gynecologic OncologyVol. 151Issue 1p6–9Published online: June 8, 2018- J. Michael Straughn Jr
- Teresa Boitano
- Haller J. Smith
- Sarah E. Dilley
- Margaret I. Liang
- Lea Novak
Cited in Scopus: 0A 32 year-old nulligravid woman with a uterine mass underwent exploratory laparotomy with myomectomy. Final pathology revealed a low-grade endometrial stromal sarcoma (ESS) with positive margins. She subsequently underwent definitive robotic hysterectomy and bilateral salpingectomy with ovarian preservation. She was diagnosed with a stage IB low-grade ESS. She is currently undergoing observation. Discussion of classification, surgical options, and adjuvant therapy is presented.